141 related articles for article (PubMed ID: 38215458)
1. Re: "Associations Between Thyroid Eye Disease and Glaucoma Among Those Enrolled in the National Institutes of Health All of Us Research Program".
Sidhu AS; Walker CEL; Al Yassin A; Xiradis N; Tweedie PJ; Kim D; Wong ELS; Lee MK; Tsoi AT; Fu MY; Ouyang MH; Gunasegaram J; Fatima A; Borchert G; Nguyen I; Agar A; Francis IC
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):356. PubMed ID: 38215458
[No Abstract] [Full Text] [Related]
2. Associations Between Thyroid Eye Disease and Glaucoma Among Those Enrolled in the National Institutes of Health All of Us Research Program: Corrigendum.
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):405. PubMed ID: 37413687
[No Abstract] [Full Text] [Related]
3. Associations Between Thyroid Eye Disease and Glaucoma Among Those Enrolled in the National Institutes of Health All of Us Research Program.
Delavar A; Radha Saseendrakumar B; Lee TC; Topilow NJ; Ting MA; Liu CY; Korn BS; Weinreb RN; Kikkawa DO; Baxter SL
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):336-340. PubMed ID: 36394556
[TBL] [Abstract][Full Text] [Related]
4. A symposium on thyroid-associated ophthalmopathy, also known as Graves' orbitopathy at the Jules Stein Eye Institute at the University of California, Los Angeles.
Douglas RS; Goldberg RA; Smith TJ
Thyroid; 2008 Sep; 18(9):931. PubMed ID: 18788916
[No Abstract] [Full Text] [Related]
5. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
6. Graves' quality of life.
Terwee CB; Wiersinga WM
Ophthalmology; 2007 Jul; 114(7):1416-7; author reply 1417-8. PubMed ID: 17613337
[No Abstract] [Full Text] [Related]
7. Access to Eye Care Providers and Glaucoma Severity in the National Institutes of Health All of Us Research Program.
Paul M; Kitayama K; Yu F; Tseng VL; Coleman AL
J Glaucoma; 2023 Dec; 32(12):1044-1051. PubMed ID: 38200661
[TBL] [Abstract][Full Text] [Related]
8. Thyroid eye disease: a review.
Weiler DL
Clin Exp Optom; 2017 Jan; 100(1):20-25. PubMed ID: 27701774
[TBL] [Abstract][Full Text] [Related]
9. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy.
Skalicky SE; Borovik AM; Masselos K; Pandya VB; Wang LW; Figueira EC; Wilcsek G; Francis IC
J Glaucoma; 2008; 17(3):249; author reply 249-50. PubMed ID: 18414116
[No Abstract] [Full Text] [Related]
12. Racial and Ethnic Disparities in Cost-Related Barriers to Medication Adherence Among Patients With Glaucoma Enrolled in the National Institutes of Health All of Us Research Program.
Delavar A; Radha Saseendrakumar B; Weinreb RN; Baxter SL
JAMA Ophthalmol; 2022 Apr; 140(4):354-361. PubMed ID: 35238904
[TBL] [Abstract][Full Text] [Related]
13. Thyroid eye disease or Graves' orbitopathy: What name to use, and why it matters.
Wagner LH; Bradley EA; Tooley AA; Ren Y; Rachmasari KN; Stan MN
Front Endocrinol (Lausanne); 2022; 13():1083886. PubMed ID: 36518254
[TBL] [Abstract][Full Text] [Related]
14. Nomenclature: thyroid-associated orbitopathy, Graves ophthalmopathy, or thyroid eye disease?
Ing EB; Madjedi K; Hurwitz JJ; Nijhawan N; Oestreicher J; Torun N
Can J Ophthalmol; 2021 Feb; 56(1):e22-e24. PubMed ID: 32702305
[No Abstract] [Full Text] [Related]
15. Extrathyroidal manifestations of thyroid disease: thyroid ophthalmopathy.
Parmar H; Ibrahim M
Neuroimaging Clin N Am; 2008 Aug; 18(3):527-36, viii-ix. PubMed ID: 18656033
[TBL] [Abstract][Full Text] [Related]
16. Euthyroid Graves' ophthalmopathy with negative autoantibodies.
Cakir M
J Natl Med Assoc; 2005 Nov; 97(11):1547-9. PubMed ID: 16334503
[TBL] [Abstract][Full Text] [Related]
17. The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.
Khazaei H; Khazaei D; Verma R; Ng J; Wilmarth PA; David LL; Rosenbaum JT
Exp Eye Res; 2021 Dec; 213():108813. PubMed ID: 34742692
[TBL] [Abstract][Full Text] [Related]
18. Re: "Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report".
Sriwijitalai W; Wiwanitkit V
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):95. PubMed ID: 34982065
[No Abstract] [Full Text] [Related]
19. Reply re: "Thyroid Eye Disease Following COVID-19 Vaccine in a Patient With a History Graves' Disease: A Case Report".
Rubinstein T
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):95-96. PubMed ID: 34982066
[No Abstract] [Full Text] [Related]
20. Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease.
Stan MN; Algeciras-Schimnich A; Murthy V; Thapa P; Araki N
Thyroid; 2022 Feb; 32(2):170-176. PubMed ID: 34714163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
